Smoking is highly prevalent among people living with HIV (PLWH) and increases cardiovascular risk. Pharmacotherapies such as nicotine replacement therapy (NRT), bupropion, and varenicline help to reduce smoking, though rates of receipt among PLWH compared with HIV-uninfected persons are unknown. Among 814 PLWH and 908 uninfected patients enrolled in the Veterans Aging Cohort Study (2012-2017) who reported current smoking, we used marginal multivariable log-linear regression models to estimate adjusted relative risks (ARR) of receiving pharmacotherapy by HIV status. We also assessed patient-level factors associated with pharmacotherapy receipt within each group. In multivariable analyses, receipt of NRT was less likely among PLWH relative to uninfected participants (ARR 0.77, 95% CI 0.67, 0.89). In both populations, documented mental health disorders and contemplation to quit were associated with greater likelihood of receiving pharmacotherapy. Further research is needed to explore potential treatment disparities.

中文翻译：

---

有和没有艾滋病毒的退伍军人戒烟药物治疗的收据和预测因素。

吸烟在 HIV 感染者 (PLWH) 中非常普遍，并且会增加心血管风险。尼古丁替代疗法 (NRT)、安非他酮和伐尼克兰等药物疗法有助于减少吸烟，但与未感染 HIV 的人相比，PLWH 的接受率尚不清楚。在退伍军人老龄化队列研究 (2012-2017) 中登记的 814 名 PLWH 和 908 名未感染患者中，他们报告了当前吸烟情况，我们使用边际多变量对数线性回归模型来估计 HIV 状态接受药物治疗的调整后相对风险 (ARR)。我们还评估了每组内与接受药物治疗相关的患者水平因素。在多变量分析中，与未感染的参与者相比，PLWH 接受 NRT 的可能性较小（ARR 0.77, 95% CI 0.67, 0.89）。在这两个人群中，记录在案的精神健康障碍和戒烟的打算与接受药物治疗的可能性更大有关。需要进一步的研究来探索潜在的治疗差异。